A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Na ïve Chronic Kidney Disease Patients Not on Dialysis

Conclusion: Roxadustat increased and maintained Hb in ESA-na ïve, partially iron-depleted NDD-CKD patients with anemia.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research